DNA and mRNA Vaccines
A section of Vaccines (ISSN 2076-393X).
Section Information
Aim and Scope
The developments of Omics sciences impacted Health and Life Sciences. In the fields of Immunology and Vaccination, these developments paved the way to broaden the use of immunization strategies. While traditionally vaccines have been based on attenuated pathogens or parts of them to stimulate the immune system, the development of Omics has broadened this usage to DNA and mRNA in novel immunological strategies against infectious and non-infectious diseases. While DNA vaccines have achieved some success, particularly in veterinary applications, the COVID-19 pandemic has led to a worldwide race for protective mRNA-based vaccines to reach the market in a timeframe never seen before.
This section is intended to cover all relevant topics related to DNA and mRNA vaccines for both infectious and non-infectious diseases, ranging from the rational design to the development and production of preclinical and clinical applications. While human therapeutics is of particular interest, manuscripts on animal therapeutics are also welcome.
Editorial Board
Topical Advisory Panel
Special Issues
Following special issues within this section are currently open for submissions:
- Selected Papers from the 1st International Electronic Conference on Vaccines: RNA Vaccines, Current Challenges and Future Developments (IECV2023) (Deadline: 30 June 2024)
- Feature Papers of DNA and mRNA Vaccines (Deadline: 30 June 2024)
- Vaccinomics: Omics-System Biology Approach in Vaccine Development (Deadline: 1 July 2024)
- mRNA-Based Vaccine Development (Deadline: 31 July 2024)
- RNA-Based Vaccines Development (Deadline: 25 August 2024)
- Recent Discoveries and Developments in RNA and DNA Vaccines (Deadline: 8 September 2024)
- Role of Next Generation Vaccines in Immunotherapeutics (Deadline: 30 November 2024)